Patents by Inventor Francois Maltais

Francois Maltais has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein kinase inhibitors and uses thereof
    Patent number: 7304071
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formulae I and V: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, T, m, n, p, Q, Q?, R1, R2, Rx, R3, and R6 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
    Type: Grant
    Filed: August 12, 2003
    Date of Patent: December 4, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: John Cochran, Jeremy Green, Michael R. Hale, Brian Ledford, Francois Maltais, Suganthini Nanthakumar
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Publication number: 20070265263
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Application
    Filed: May 16, 2007
    Publication date: November 15, 2007
    Inventors: Jingrong Cao, Jeremy Green, Michael Hale, Francois Maltais, Judy Straub, Oing Tang, Alex Aronov
  • Pyrazole-derived kinase inhibitors and uses thereof
    Patent number: 7279476
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where B, R1, n, R3, Q, and R4 are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: January 5, 2005
    Date of Patent: October 9, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Oing Tang, Francois Maltais, James Walter Janetka, Michael Robin Hale
  • Deuterated hepatitis C protease inhibitors
    Publication number: 20070225297
    Abstract: A deuterated ?-ketoamido steric specific compound of the formula wherein D denotes a deuterium atom on a steric specific carbon atom.
    Type: Application
    Filed: March 14, 2007
    Publication date: September 27, 2007
    Inventors: Robert Perni, Youssef Bennani, Gregor Zlokarnik, Gerald Tanoury, Minzhang Chen, Young Jung, Raymond Forslund, Francois Maltais
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Patent number: 7253187
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein Z1 and Z2 are each independently nitrogen or CH and Ring A, TmR1, QR2, UnR3, and Sp are as described in the specification. The compounds are especially useful as inhibitors of ERK2 and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Grant
    Filed: February 3, 2004
    Date of Patent: August 7, 2007
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jingrong Cao, Jeremy Green, Michael Hale, Francois Maltais, Judy Straub, Qing Tang, Alex Aronov
  • Heterocyclic protein kinase inhibitors and uses thereof
    Patent number: 7244735
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, p, Q, R1, R2, R3, and R3 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: July 17, 2007
    Assignee: Vertex Pharmaceuticals Inc.
    Inventors: Judith Straub, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Alex Aronov, Guy Bemis
  • Pyrazole-derived kinase inhibitors and uses thereof
    Patent number: 7183307
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein B, R1, n, R3, Q and R4 are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: May 3, 2004
    Date of Patent: February 27, 2007
    Assignee: Vertex Pharmaceuticals Incroporated
    Inventors: Michael Robin Hale, James Walter Janetka, Francois Maltais, Qing Tang
  • Selective inhibitors of ERK protein kinase and uses thereof
    Publication number: 20060160807
    Abstract: Described herein are compounds that are useful as ERK2 inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Application
    Filed: December 20, 2005
    Publication date: July 20, 2006
    Inventors: Alexander Aronov, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Ion channel modulators and methods of use
    Publication number: 20060160817
    Abstract: In general, the invention relates to compounds useful as ion channel modulators. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are useful as inhibitors of voltage-gated sodium channels and/or calcium channels.
    Type: Application
    Filed: November 3, 2005
    Publication date: July 20, 2006
    Inventors: Esther Martinborough, Nicole Zimmermann, Robert Perni, Michael Arnost, Upul Bandarage, Francois Maltais, Guy Bemis
  • Inhibitors of ERK protein kinase and uses thereof
    Publication number: 20060142572
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring A, Z1, Z2, U, Q, R1, R2, and L are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including proliferative disorders such as cancer.
    Type: Application
    Filed: December 13, 2005
    Publication date: June 29, 2006
    Inventors: Gabriel Martinez-Botella, Alex Aronov, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Pyrazole compositions useful as inhibitors of erk
    Patent number: 7056944
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1-4, Q, and T are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 17, 2003
    Date of Patent: June 6, 2006
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, Xiaoling Xie, Jeremy Green, Jingrong Cao, Christopher Baker, Francois Maltais, James Janetka, Guy Bemis, Michael Mullican, Judith Straub, Qing Tang, Robert Mashal
  • Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
    Publication number: 20060106069
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: May 13, 2005
    Publication date: May 18, 2006
    Inventors: Gabriel Martinez-Botella, Michael Hale, Francois Maltais, Judith Straub, Qing Tang
  • Prodrugs of an ERK protein kinase inhibitor
    Publication number: 20060058318
    Abstract: The present invention relates to compounds useful of inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: May 13, 2005
    Publication date: March 16, 2006
    Inventors: Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Judith Straub, Qing Tang
  • Triazole-derived kinase inhibitors and uses thereof
    Publication number: 20050272789
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where Ht, R2, T, and m are as described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Application
    Filed: June 23, 2005
    Publication date: December 8, 2005
    Inventors: Michael Hale, Francois Maltais
  • Triazole-derived kinase inhibitors and uses thereof
    Patent number: 6962936
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where Ht, R2, T, and m are as described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: April 26, 2002
    Date of Patent: November 8, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, Francois Maltais
  • Heterocyclic protein kinase inhibitors and uses thereof
    Publication number: 20050245499
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors of formula I: or a pharmaceutically acceptable salt thereof, wherein Ring B, Z1, Z2, U, p, Q, R1, R2, R3, and R3 are as defined herein. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including stroke, inflammatory disorders, autoimmune diseases such as SLE lupus and psoriasis, proliferative disorders such as cancer, and conditions associated with organ transplantation.
    Type: Application
    Filed: December 2, 2004
    Publication date: November 3, 2005
    Inventors: Judith Straub, Michael Hale, Francois Maltais, Gabriel Martinez-Botella, Alex Aronov, Guy Bemis
  • Heterocyclic inhibitors of ERK2 and uses thereof
    Publication number: 20050234059
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: wherein A1, A2, TmR1, X, R2, R3, R9, R12, and R13 are as described in the specification. The compounds are especially useful as inhibitors of ERK2, Aurora2, GSK3, CDK2, AKT3, and ROCK protein kinases and for treating diseases in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, neurodegenerative disorders, inflammatory disorders, restenosis, diabetes, and cardiovascular disease.
    Type: Application
    Filed: March 10, 2005
    Publication date: October 20, 2005
    Inventors: Michael Robin Hale, Francois Maltais, Qing Tang, Judith Straub, Alexander Aronov
  • Pyrazole-derived kinase inhibitors and uses thereof
    Publication number: 20050215550
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where B, R1, n, R3, Q, and R4 are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Application
    Filed: January 5, 2005
    Publication date: September 29, 2005
    Inventors: Oing Tang, Francois Maltais, James Janetka, Michael Hale
  • Pyrazole compositions useful as inhibitors of ERK
    Patent number: 6949580
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors having the formula: where R1, R2, T and Ht are described in the specification. The compounds are useful for treating disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: October 16, 2003
    Date of Patent: September 27, 2005
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael Hale, James Janetka, Francois Maltais
  • Isoxazole compositions useful as inhibitors of ERK
    Publication number: 20050090536
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein, kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Application
    Filed: July 24, 2003
    Publication date: April 28, 2005
    Inventors: Michael Hale, James Janetka, Francois Maltais, Jingrong Cao, Robert Mashal